Wedbush Raises Earnings Estimates for ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Stock analysts at Wedbush lifted their Q2 2025 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research report issued to clients and investors on Monday, May 5th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.48) per share for the quarter, up from their previous forecast of ($0.49). Wedbush has a “Outperform” rating and a $20.00 price objective on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.17) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.84) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.90) EPS and FY2028 earnings at ($1.24) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.09.

Other equities research analysts have also issued reports about the company. Oppenheimer dropped their price target on ORIC Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. raised their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday. Guggenheim reissued a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, May 5th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $19.17.

ORIC Pharmaceuticals Stock Down 4.5 %

ORIC stock opened at $5.08 on Thursday. ORIC Pharmaceuticals has a 52 week low of $3.90 and a 52 week high of $14.67. The company has a market cap of $361.13 million, a price-to-earnings ratio of -2.79 and a beta of 1.37. The business has a fifty day simple moving average of $5.90 and a 200-day simple moving average of $8.07.

Hedge Funds Weigh In On ORIC Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of ORIC Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 3,215,887 shares of the company’s stock worth $17,945,000 after acquiring an additional 12,098 shares during the last quarter. TD Asset Management Inc grew its stake in ORIC Pharmaceuticals by 3.3% during the 1st quarter. TD Asset Management Inc now owns 152,700 shares of the company’s stock valued at $852,000 after purchasing an additional 4,900 shares in the last quarter. Legato Capital Management LLC purchased a new stake in ORIC Pharmaceuticals during the 1st quarter worth approximately $109,000. Victory Capital Management Inc. increased its stake in shares of ORIC Pharmaceuticals by 54.1% in the first quarter. Victory Capital Management Inc. now owns 150,260 shares of the company’s stock worth $838,000 after buying an additional 52,760 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in ORIC Pharmaceuticals by 137.1% in the first quarter. New York State Common Retirement Fund now owns 38,486 shares of the company’s stock valued at $215,000 after acquiring an additional 22,257 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.